Adela Appoints Precision Medicine Veteran Lisa Alderson as CEO
Retrieved on:
木曜日, 12月 14, 2023
FOSTER CITY, Calif., Dec. 14, 2023 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, today announced the appointment of Lisa Alderson as Chief Executive Officer, following an extensive, nationwide search. Ms. Alderson is uniquely positioned to guide Adela through product scaling and commercialization, based on her prior leadership roles at Genome Medical, Invitae, and Genomic Health.
Key Points:
- "We are thrilled to appoint Ms. Alderson to lead Adela through its next phase of growth", said David Scheer, Chairman of Adela's Board of Directors.
- Serving most recently as interim CEO to Adela, she has already demonstrated her ability to engage and lead this mission-driven organization in delivering results."
- Ms. Alderson previously co-founded and served as the CEO of Genome Medical, the leading genomic care delivery company enabling broad-based access to genomic medicine.
- "I'm excited to guide Adela through product development, commercialization and growth with the goal of applying our innovative technology to advance patient care in oncology," said Lisa Alderson, CEO, Adela.